American Society of Hematology

Figure 1.

$Coagulant activity of human milk (HM). (A) Dilutions of HM (n = 6) were added to human plasma as described in “Methods.” Percentages shown are the final concentrations of HM (vol/vol). (B) Images of EVs from milk labeled with annexin V–gold nanoparticles at 2 magnifications: scale bar 1 µm and 100 nm. At higher magnification, the characteristic lipid bilayer of EVs is visible. (C) Milk was fractionated by ultracentrifugation, and presence of TF was determined by western blot for all donors. Human brain lysate was used as positive control. TF was detectable in the pellet and below the detection limit in the supernatant. (D) Milk-, pellet-, and supernatant-induced (1% final concentration; vol/vol) clotting of plasma in the absence and presence of anti-TF. *P < .05, **P < .01, ***P < .001. CF, carbon film; n.s., nonsignificant.$

Coagulant activity of human milk (HM). (A) Dilutions of HM (n = 6) were added to human plasma as described in “Methods.” Percentages shown are the final concentrations of HM (vol/vol). (B) Images of EVs from milk labeled with annexin V–gold nanoparticles at 2 magnifications: scale bar 1 µm and 100 nm. At higher magnification, the characteristic lipid bilayer of EVs is visible. (C) Milk was fractionated by ultracentrifugation, and presence of TF was determined by western blot for all donors. Human brain lysate was used as positive control. TF was detectable in the pellet and below the detection limit in the supernatant. (D) Milk-, pellet-, and supernatant-induced (1% final concentration; vol/vol) clotting of plasma in the absence and presence of anti-TF. *P < .05, **P < .01, ***P < .001. CF, carbon film; n.s., nonsignificant.

This Feature Is Available To Subscribers Only